

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

THURSDAY, FEBRUARY 29	
7:30 - 9:00 AM	BREAKFAST
9:00 - 9:15 AM	BREAK
9:15 - 10:15 AM	WELCOME & KENNETH P. JOHNSON MEMORIAL LECTURE
Pioneering B-Cell Therapies <i>Anne Cross, Washington University in St. Louis</i>	
10:15 - 10:30 AM	BREAK
10:30 - 12:05 PM	S1. SESSION 1 – EMERGING CONCEPTS IN MS
<p>Theme: Highlighting studies that inform our understanding of the pathogenic mechanisms in MS, introduce novel measures to capture disease activity and advance treatment options for affected individuals. <i>This session will be comprised of platform presentations by Young Investigators selected from submitted abstracts. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.</i></p> <p>Chairs: <i>Jiwon Oh, University of Toronto</i> <i>Benjamin Segal, The Ohio State University</i></p>	
10:30 – 10:35	Introduction
10:35 – 10:50	S1.1 Synaptic Injury in the IPL of the Retina is a Predictor of Progression in Multiple Sclerosis <i>Christian Cordano, University of California San Francisco</i>
10:50 – 11:05	S1.2 Hypoxia-Related Impairment of Brain Function in Multiple Sclerosis: Insights from Near-Infrared Spectroscopy <i>Ateyeh Soroush, University of Calgary</i>
11:05 – 11:20	S1.3 Restoring the Multiple Sclerosis Associated Imbalance of Gut Indole Metabolites Promotes Remyelination and Suppresses Neuroinflammation <i>Larissa Jank, Johns Hopkins University</i>
11:20 – 11:35	S1.4 Multimodal Molecular Profiling of Exosome-Enriched Extracellular Vesicles from B Cells in Multiple Sclerosis Patients: Insights into Potential Toxicity Mechanisms <i>Gautier Breville, University of Pennsylvania</i>
11:35 – 11:50	S1.5 Mannose Receptor C Type 2 as a Novel Marker for Brain-Infiltrating CD8+ Cytotoxic T cells in Multiple Sclerosis <i>Bettina Zierfuss, University of Montreal</i>
11:50 – 12:05	S1.6 Mapping the Functional Interactome in MS Lesions Relevant to Remyelination Failure <i>Milos Opacic, Yale University</i>
12:05 - 1:30 PM	LUNCH IN THE HUB

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

Thursday, February 29th continued

12:20 - 1:20 PM	SS2. INDUSTRY SUPPORTED CE SATELLITE SYMPOSIUM 2
New Frontiers in Optimizing Patient Outcomes in Multiple Sclerosis: Strategies for Early Intervention to Address Progression Independent of Relapse	
<p><i>This CE activity is provided by AGILE. This independent Industry Supported Satellite Symposium is supported by an educational grant from EMD Serono, Inc. EMD Serono, Inc. is the healthcare business of Merck KGaA, Darmstadt, Germany.</i></p> <p>Click here to learn more.</p>	
12:30 - 1:15 PM	BRAIN EXCHANGE 1: GENDER PARITY IN CAREER PROGRESSION
	Moderators: Ellen Mowry, <i>Johns Hopkins University</i> and Catherine Larochelle, <i>University of Montreal</i>
	BRAIN EXCHANGE 2: BARRIERS TO PERSONALIZED MEDICINE
	Moderators: Fiona Costello, <i>University of Calgary</i> and Pavan Bhargava, <i>Johns Hopkins University</i>
1:30 - 2:30 PM	AP1. LACTRIMS SYMPOSIUM - BRINGING DOWN THE WALLS IN MULTIPLE SCLEROSIS
<p>Chairs: Fernando Gracia, <i>LACTRIMS President, Hospital Santo Tomás, Universidad Interamericana de Panamá</i> and Carlos Navas, <i>Clinica Universitaria Colsanitas - Hospital San Jose</i></p>	
1:30 – 1:35	Introduction
1:35 – 1:50	AP1.1 Setting the Agenda for MS Research in Latin America Results from a Delphi Consensus Juan Ignacio Rojas, <i>Hospital Universitario de CEMIC</i>
1:50 – 2:05	AP1.2 Big Data Research in MS in LATAM: Future Prospects and Gaps Jefferson Becker, <i>Pontificia Universidade Católica do Rio Grande do Sul (PUCRS)</i>
2:05 – 2:20	AP1.3 Breaking Down Race and Ethnicity in MS Across LATAM Teresa Corona, <i>Universidad Nacional Autónoma de México</i>
2:20 – 2:30	Q & A
2:30 - 2:45 PM	BREAK
2:45 - 4:15 PM	S2. SESSION 2 - MS ACROSS POPULATIONS AND ACCESS TO CARE
<p>Theme: The session will focus on barriers to equitable research, care delivery, and the interplay of genetics and social determinants of health in multiple sclerosis. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i></p> <p>Chairs: Dalia Rotstein, <i>University of Toronto</i> Kathleen Munger, <i>MultiCare Neuroscience & Sleep Medicine</i></p>	
2:45 - 2:50	Introduction
2:50 - 3:05	S2.1 Accelerating Research Through Open Science : A Funder's Perspective Viviane Poupon, <i>Brain Canada</i>
3:05 - 3:20	S2.2 Improving Access to MS Care Through Technology Marisa McGinley, <i>Cleveland Clinic</i>
3:20 - 3:35	S2.3 Debate: Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics (YES) Philip De Jager, <i>Columbia University</i>
3:35 - 3:50	S2.4 Debate: Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics (NO) Annette Langer-Gould, <i>Kaiser Permanente</i>
3:50 - 4:15	Q & A
4:15 - 4:30 PM	BREAK

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

Thursday, February 29th continued

4:30 - 5:35 PM	CE1. CUTTING EDGE DEVELOPMENTS
<p>Theme: Cutting-edge platform presentations selected from submitted abstracts. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.</p> <p>Chairs: Scott Zamvil, <i>University of California - San Francisco</i> Shannon Dunn, <i>University of Toronto</i></p>	
4:30 – 4:35	Introduction
4:35 – 4:50	CE1.1 Obesity Negatively Affects Disease Progression, Cognitive Functioning, and Quality of Life in People with Multiple Sclerosis Lars Alfredsson, <i>Karolinska Institute</i>
4:50 – 5:05	CE1.2 Innate Immune Regulator NLRX1 protects the Anterior Visual Pathway Against Inflammatory Neurodegeneration Marjan Gharagozloo, <i>Johns Hopkins University</i>
5:05 – 5:20	CE1.3 Spatiotemporal Profiling of Senescence-Associated Secretory Phenotype at the Brain Barriers in a Marmoset Model of Multiple Sclerosis Jing-Ping Lin, <i>National Institutes of Health</i>
5:20 – 5:35	CE1.4 Assessment of Biological Aging in People with Multiple Sclerosis Using Epigenetic Clocks and p16INK4a Yinan Zhang, <i>The Ohio State University</i>
5:35 - 6:00 PM	COCKTAIL BREAK IN THE HUB
6:00 - 7:30 PM	POSTER SESSION 1
7:45 - 9:00 PM	IWIMS EVENT - TRAILBLAZERS AND INNOVATORS IN MS
<p>All are welcome and encouraged to join iWiMS for a special session at the ACTRIMS Forum. This session will feature an enlightening and empowering panel discussion featuring trailblazing women neurologists in the field of multiple sclerosis (MS). The panelists will share the challenges and rewards of going against the grain, proposing new or initially unpopular ideas, and fighting inequities in the field.</p>	
FRIDAY, MARCH 1	
7:30 - 9:00 AM	BREAKFAST
8:00 - 9:00 AM	SS3. INDUSTRY SUPPORTED CE SATELLITE SYMPOSIUM 3
<p>BTK Inhibitors Across the Spectrum of MS: Investigator Updates & Expert Insights</p> <p><i>This CE activity is jointly provided by Letters & Sciences and Partners for Advancing Clinical Education. This independent Industry Supported Satellite Symposium is supported by an educational grant from Sanofi.</i></p>	
9:00 - 9:15 AM	BREAK

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

Friday, March 1 continued

9:15 - 10:45 AM	S3. SESSION 3 – CNS BARRIERS THINKING OUTSIDE THE BOX
<p>Theme: Exploring CNS barriers and their associated cells outside the traditional model of the blood brain barrier. Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</p> <p>Chairs: Stephanie Zandee, <i>Université de Montréal</i> Jessica Williams, <i>Cleveland Clinic</i></p>	
9:15 – 9:20	Introduction
9:20 - 9:35	S3.1 Ependymal Cells and Their Role in CNS Inflammation Jo Anne Stratton, <i>McGill University</i>
9:35 - 9:50	S3.2 Choroid Plexus as Route of CNS Inflammation Maria Lehtinen, <i>Boston Children's Hospital, Harvard Medical School</i>
9:50 - 10:05	S3.3 Imaging the Choroid Plexus Niels Bergsland, <i>University at Buffalo</i>
10:05 – 10:20	S3.4 Mechanisms of Blood Brain Barrier Disruption in Neuroinflammatory Disease Dimitrios Davalos, <i>Cleveland Clinic</i>
10:20 – 10:45	Q & A
10:45 - 11:00 AM	Break
11:00 AM - 12:05 PM	CE2. CUTTING EDGE DEVELOPMENTS
<p>Theme: Cutting-edge platform presentations selected from submitted abstracts. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.</p> <p>Chairs: Kevin O'Connor, <i>Yale University</i> Carlos Camara-Lemarroy, <i>University of Calgary</i></p>	
11:00 – 11:05	Introduction
11:05 – 11:20	CE2.1 Probing Viral Specificity of Clonally Expanded CD8+ T Cells in the Cerebrospinal Fluid in Multiple Sclerosis Fumie Hayashi, <i>University of California, San Francisco</i>
11:20 – 11:35	CE2.2 Increased Aerobic Glycolysis is Present in Early Multiple Sclerosis and Varies by Treatment Bradley Judge, <i>Washington University in St. Louis</i>
11:35 – 11:50	CE2.3 Clemastine Fumarate Accelerates Accumulation of Disability in Progressive Multiple Sclerosis by Enhancing Pyroptosis Joanna Kocot, <i>National Institutes of Health</i>
11:50 – 12:05	CE2.4 Association Between Paramagnetic Rim Lesions and Future Cognitive Performance in Multiple Sclerosis Hannah Schwartz, <i>Cornell University</i>

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

Friday, March 1 continued

12:05 - 1:30 PM	LUNCH IN THE HUB
12:20 - 1:20 PM	SS4. INDUSTRY SUPPORTED CE SATELLITE SYMPOSIUM 4
<p>Neuromyelitis Optica Spectrum Disorder: Diagnosis and Treatment Insights for the Multiple Sclerosis Team This CE activity is provided by Vindico Medical Education. This independent Industry Supported Satellite Symposium is supported by an educational grant from Horizon Therapeutics USA, Inc.</p>	
12:30 - 1:15 PM	BRAIN EXCHANGE 3: BARRIERS TO IMAGING MYELIN
	Moderators: Shannon Kolind, <i>University of British Columbia</i> and Erin Beck, <i>Mount Sinai</i>
	BRAIN EXCHANGE 4: DIFFERENTIAL DIAGNOSIS: BARRIERS AND CHALLENGES
	Moderators: Andy Solomon, <i>University of Vermont</i> and Marwa Kaisey, <i>Cedars-Sinai</i>
1:30 - 2:30 PM	AP2. EUROPEAN CHARCOT FOUNDATION SYMPOSIUM - MOVING THE PATIENT AT THE CENTER
Chairs: Giancarlo Comi, <i>IRCCS San Raffaele Hospital and University</i> and Mark Freedman, <i>University of Ottawa</i>	
1:30 – 1:35	Introduction
1:35 – 1:50	AP2.1 PROs, From Clinical Trials to Clinical Practice and Vice-Versa: Lesson Learnt from Global PROMS Initiative Paola Zaratini, <i>Italian MS Society & Foundation</i>
1:50 – 2:05	AP2.2 Are the Wearable Devices Mature to Monitor MS? Letizia Leocani, <i>Vita-Salute San Raffaele University</i>
2:05 – 2:20	AP2.3 PROs in MS Registries and Clinical Care Robert McBurney, <i>Accelerated Cure Project for Multiple Sclerosis</i>
2:20 – 2:30	Q & A
2:30 - 2:45 PM	BREAK
2:45 - 4:15 PM	S4. SESSION 4 – BARRIERS TO NEURAL REPAIR
<p>Theme: Basic and clinical topics on barriers to, and proposed solutions for, remyelination. Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</p>	
Chairs:	
Jason Plemel, <i>University of Alberta</i>	
Veronique Miron, <i>University of Toronto</i>	
2:45 – 2:50	Introduction
2:50 - 3:05	S4.1 Next Generation Animal Models for Studying Remyelination in MS Jennifer Orthmann - Murphy, <i>University of Pennsylvania</i>
3:05 - 3:20	S4.2 Engineering 3D Platforms to Overcome Barriers of Drug Discovery for MS Krystyn Van Vliet, <i>Cornell University</i>
3:20 - 3:35	S4.3 Immune Barriers to Remyelination Jeffrey Huang, <i>Georgetown University</i>
3:35 - 3:50	S4.4 Barriers in Remyelination Trials Ari Green, <i>University of California, San Francisco</i>
3:50 - 4:15	Q & A
4:15 - 4:30 PM	BREAK
4:30 - 5:30 PM	BP1. NMSS BARANCIK AWARD PRESENTATION AND TALK
Dr. Segio Baranzini, PhD, <i>University of California, San Francisco</i>	
5:30 - 6:00 PM	COCKTAIL BREAK IN THE HUB
6:00 - 7:30 PM	POSTER SESSION 2

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

SATURDAY, MARCH 2

7:30 - 9:00 AM	BREAKFAST
8:00 - 9:30 AM	AP3. JOINT NAIMS & IMSVISUAL SYMPOSIUM: VASCULAR/METABOLIC/ADVANCED IMAGING USING PORTABLE PLATFORMS
Chairs: NAIMS: Joel Stein, <i>University of Pennsylvania</i> and Shannon Kolind, <i>University of British Columbia</i> IMSVISUAL: Ahmed Toosy, <i>University College London</i> and Angela Vidal-Jordana, <i>Multiple Sclerosis Centre of Catalonia-Vall d'Hebron University Hospital</i>	
8:00 – 8:05	Introduction
8:05 – 8:25	AP3.1 Adaptive Optics in MS Daniel Harrison, <i>University of Maryland</i>
8:25 – 8:45	AP3.2 Portable MRI for Multiple Sclerosis Joel Stein, <i>University of Pennsylvania</i>
8:45 – 8:55	AP3.3 Complement Dependent Cytotoxicity Drives Retinal Ganglion Cell Loss in a Novel In Vivo Model of Neuromyelitis Optica Oliver Gramlich, <i>University of Iowa</i>
8:55 – 9:05	AP3.4 Feasibility and Tolerability of Portable, Low-Field Brain MRI for Outpatients with Multiple Sclerosis Andrew Ham, <i>Massachusetts General Hospital</i>
9:05 – 9:15	AP3.5 In-vivo Investigation of the Modulation of Retinal Atrophy by Oral Disease Modifying Therapies in Relapsing Multiple Sclerosis: A Prospective Study Omar Ezzedin, <i>Johns Hopkins University</i>
9:15 – 9:25	AP3.6 Portable Ultra-Low Field MRI for Progressive Multifocal Leukoencephalopathy: Feasibility and Diagnostic Potential in Comparison to High-Field MRI Serhat Okar, <i>National Institutes of Health</i>
9:30 - 9:45 AM	BREAK
9:45 - 11:15 AM	S5. SESSION 5 – REHABILITATION WITHOUT BORDERS
Theme: Examine the mechanisms of rehabilitation and how to further rehabilitation trials. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i>	
Chairs: Kathy Zackowski, <i>National MS Society</i> Gabrielle Macaron, <i>Université de Montréal</i>	
9:45 - 9:50	Introduction
9:50 - 10:05	S5.1 Exercise as a Therapeutic Intervention in Multiple Sclerosis Lara Pilutti, <i>University of Ottawa</i>
10:05 - 10:20	S5.2 Basic Mechanisms That May Underpin Repair/Rehabilitation Don Mahad, <i>University of Edinburgh</i>
10:20 - 10:35	S5.3 Cognitive Rehabilitation in Multiple Sclerosis: What Has Been Achieved? Nancy Chiaravalloti, <i>Kessler Foundation</i>
10:35 - 10:50	S5.4 Rehabilitation Clinical Trials: Barriers and Unmet Needs Robert Motl, <i>University of Illinois at Chicago</i>
10:50 - 11:15	Q & A
11:15 - 11:30 AM	BREAK

Saturday, March 2 continued

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

11:30 AM - 12:15 PM	LB1: LATE-BREAKING RESEARCH & CLINICAL TRIALS (NON-CE SESSION)
Chairs: Myla Goldman, <i>Virginia Commonwealth University</i> Amit Bar-Or, <i>University of Pennsylvania</i>	
11:30 – 11:35	Introduction
11:35 – 11:45	LB 1.1 Effects of Repeated Autologous Mesenchymal Stem Cell Transplantation On Cognition And Serum Biomarkers In Progressive MS: Interim Analysis Of An Open Label Extension Trial Dimitrios Karussis, <i>Hadassah University</i>
11:45 – 11:55	LB 1.2 Primary Outcome of a Phase 2 Clinical Trial of Tolebrutinib, A Brain-penetrant BTK Inhibitor, For the Modulation Of Chronically Inflamed White Matter Lesions In MS María Gaitán, <i>National Institutes of Health</i>
11:55 – 12:05	LB 1.3 Identification Of CVL-1001 And CVL-2001 As Selective Brain Penetrant Therapeutics for Enhanced Remyelination Brad Lang, <i>Convelo</i>
12:05 – 12:15	LB 1.4 Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase 3 evolutionRMS 1 and 2 Trials Xavier Montalban, <i>CEMCA</i>
12:15 - 1:30 PM	LUNCH
12:30 - 1:15 PM	DIFFERENTIAL DIAGNOSIS IN PEDIATRIC AND LATE ONSET MULTIPLE SCLEROSIS: AN UPDATE FROM THE ACTRIMS DIFFERENTIAL DIAGNOSIS CONSORTIUM
12:30 – 12:42	Background and MS Mimics for LOMS Le Hua, <i>Cleveland Clinic</i>
12:42 – 12:54	Mimics for POMS Cheryl Hemingway, <i>Great Ormond Street Hospital for Children (London)</i>
12:54 – 1:06	Future Directions and the Role of Imaging/Biomarkers Orhun Kantarci, <i>Mayo Clinic</i>
1:06 – 1:15	Q & A
1:30 - 3:00 PM	S6. SESSION 6 – BARRIERS IN CLINICAL TRIALS
Theme: Effective clinical trial design including representation, outcome optimization, and participant selection. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i>	
Chairs: Francesca Bagnato, <i>Vanderbilt University</i> Annette Okai, <i>North Texas Institute of Neurology and Headache</i>	
1:30 - 1:35	Introduction
1:35 - 1:50	S6.1 Selecting Informative Patients for Phase 2 Progressive Trials in MS Marcus Koch, <i>University of Calgary</i>
1:50 - 2:05	S6.2 Ensuring Representation in Clinical Trials Mitzi Joi Williams, <i>Joi Life Wellness</i>
2:05 - 2:20	S6.3 Visual System as a Model for Neuroprotection Trials Shiv Saidha, <i>Johns Hopkins University</i>
2:20 - 2:35	S6.4 Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation María Inés Gaitán, <i>National Institutes of Health</i>
2:35 - 3:00	Q & A
3:00 - 3:15 PM	AWARDS PRESENTATION & CLOSING